No increased risk of severe COVID-19 in asthma treated with biologics

Basit Öğe Kaydı
dc.authorid/0000-0002-1505-4293
dc.authoridOZSEKER, ZEYNEP FERHAN/0000-0002-3387-4818
dc.contributor.authorBeyaz, Sengul
dc.contributor.authorErecan, Emircan
dc.contributor.authorMutlu, Pinar
dc.contributor.authorOzseker, Zeynep Ferhan
dc.date.accessioned2025-01-27T20:38:57Z
dc.date.available2025-01-27T20:38:57Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBACKGROUND AND AIM: Biologics can be used safely for patients with severe asthma during the coronavirus pandemic, but there is still a lack of information regarding their effects during SARS-CoV-2 infection. The aim of this study was to evaluate the impact of biologic therapies on the course of SARS-CoV-2 infection and to assess the outcome of COVID-19 for severe asthmatics in pandemic conditions. METHODS: A total of 100 severe asthma patients treated with biologics (7 treated with dupilumab, 22 with mepolizumab, and 71 with omalizumab) were included. Patients' demographic, clinical, and laboratory findings as well as the course of the COVID-19 disease were evaluated. RESULTS: Of the total 100 patients, 15% of patients were diagnosed with COVID-19. There were no significant differences between SARS-CoV-2 positive and negative patient groups in terms of demographic features, atopy, comorbidity, duration of asthma, and duration of biological use. The body mass index (BMI) was higher in the SARS-CoV-2 negative group than the positive group (p=0.005). Asthma exacerbation during COVID-19 was observed in 3 patients, and only 2 were hospitalized for 5 days. SARS-CoV-2 positive group exhibited lower eosinophil and lymphocyte levels when infected with COVID-19 than before COVID-19 (p=0.01 and p=0.0009 respectively). CONCLUSIONS: The rate of COVID-19 infection was higher in patients with severe asthma receiving biologics than in the general population. However, it can be speculated that treatment with biologics may have protection against severe COVID-19 and mortality. Further studies are required to investigate the role of biologic agents, which affect the level and function of eosinophils in viral infections, especially SARS-CoV-2.
dc.identifier.doi10.14744/ejp.2022.9821
dc.identifier.endpage94
dc.identifier.issn2148-3620
dc.identifier.issn2148-5402
dc.identifier.issue2
dc.identifier.startpage85
dc.identifier.trdizinid1120705
dc.identifier.urihttps://doi.org/10.14744/ejp.2022.9821
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1120705
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23814
dc.identifier.volume24
dc.identifier.wosWOS:000882922900002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherKare Publ
dc.relation.ispartofEurasian Journal of Pulmonology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectAsthma
dc.subjectbiologic agents
dc.subjectCOVID-19
dc.subjectdupilumab
dc.subjectmepolizumab
dc.subjectomalizumab
dc.titleNo increased risk of severe COVID-19 in asthma treated with biologics
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu